Cargando…
Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates
Despite advances in understanding of ovarian cancer biology, the progress in translation of research findings into new therapies is still slow. It is associated in part with limitations of commonly used cancer models such as cell lines and genetically engineered mouse models that lack proper represe...
Autores principales: | Cybula, Magdalena, Bieniasz, Magdalena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959092/ https://www.ncbi.nlm.nih.gov/pubmed/35359749 http://dx.doi.org/10.18632/oncotarget.28220 |
Ejemplares similares
-
Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research
por: Cybula, Magdalena, et al.
Publicado: (2021) -
Multi-kinase targeted therapy as a promising treatment strategy for ovarian tumors expressing sfRon receptor
por: Wang, Luyao, et al.
Publicado: (2020) -
Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates
por: De Lellis, Laura, et al.
Publicado: (2021) -
Upregulation of Succinate Dehydrogenase (SDHA) Contributes to Enhanced Bioenergetics of Ovarian Cancer Cells and Higher Sensitivity to Anti-Metabolic Agent Shikonin
por: Wang, Lin, et al.
Publicado: (2022) -
Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma
por: Drumond-Bock, Ana Luiza, et al.
Publicado: (2023)